3893 related articles for article (PubMed ID: 31294382)
21. Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review.
Bashir NS; Hughes A; Ungar WJ
MDM Policy Pract; 2023; 8(1):23814683231156433. PubMed ID: 36860664
[TBL] [Abstract][Full Text] [Related]
22. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ;
J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis.
Targownik LE; Kaplan GG; Witt J; Bernstein CN; Singh H; Tennakoon A; Aviña Zubieta A; Coward SB; Jones J; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN; Benchimol EI
Am J Gastroenterol; 2020 Jan; 115(1):128-137. PubMed ID: 31895723
[TBL] [Abstract][Full Text] [Related]
24. The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.
Shaffer SR; Kuenzig ME; Windsor JW; Bitton A; Jones JL; Lee K; Murthy SK; Targownik LE; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Tandon P; St-Pierre J; Natt N; Davis T; Weinstein J; Im JHB; Benchimol EI; Kaplan GG; Goddard Q; Gorospe J; Bergevin M; Silver K; Bowles D; Stewart M; Pearlstein M; Dawson EH; Bernstein CN
J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S45-S54. PubMed ID: 37674503
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada.
Benchimol EI; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Siddiq S; Windsor JW; Carroll MW; Coward S; El-Matary W; Griffiths AM; Jones JL; Kuenzig ME; Lee L; Mack DR; Mawani M; Otley AR; Singh H; Targownik LE; Weizman AV; Kaplan GG
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S1-S5. PubMed ID: 31294380
[TBL] [Abstract][Full Text] [Related]
26. Caregiver- and patient-directed interventions for dementia: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2008; 8(4):1-98. PubMed ID: 23074509
[TBL] [Abstract][Full Text] [Related]
27. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
[TBL] [Abstract][Full Text] [Related]
28. The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life.
Jones JL; Nguyen GC; Benchimol EI; Bernstein CN; Bitton A; Kaplan GG; Murthy SK; Lee K; Cooke-Lauder J; Otley AR
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S42-S48. PubMed ID: 31294384
[TBL] [Abstract][Full Text] [Related]
29. The 2023 Impact of Inflammatory Bowel Disease in Canada: Indirect (Individual and Societal) and Direct Out-of-Pocket Costs.
Kuenzig ME; Im JHB; Coward S; Windsor JW; Kaplan GG; Murthy SK; Benchimol EI; Bernstein CN; Bitton A; Jones JL; Lee K; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Jones May T; Tabatabavakili S; Jogendran R; Weinstein J; Khan R; Hazan E; Browne M; Davis T; Goddard Q; Gorospe J; Latos K; Mason K; Kerr J; Balche N; Sklar A; Targownik LE
J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S16-S22. PubMed ID: 37674495
[TBL] [Abstract][Full Text] [Related]
30. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
31. Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.
Sin AT; Damman JL; Ziring DA; Gleghorn EE; Garcia-Careaga MG; Gugig RR; Hunter AK; Burgis JC; Bass DM; Park KT
Inflamm Bowel Dis; 2015 Jun; 21(6):1368-77. PubMed ID: 25839776
[TBL] [Abstract][Full Text] [Related]
32. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
[TBL] [Abstract][Full Text] [Related]
33. Health Services Utilization and Specialist Care in Pediatric Inflammatory Bowel Disease: A Multiprovince Population-Based Cohort Study.
Kuenzig ME; Bitton A; Carroll MW; Otley AR; Singh H; Kaplan GG; Stukel TA; Mack DR; Jacobson K; Griffiths AM; El-Matary W; Targownik LE; Nguyen GC; Jones JL; Murthy SK; Bernstein CN; Lix LM; Peña-Sánchez JN; Dummer TJB; Spruin S; Fung SG; Nugent Z; Coward S; Cui Y; Coulombe J; Filliter C; Benchimol EI
Inflamm Bowel Dis; 2024 Feb; ():. PubMed ID: 38366807
[TBL] [Abstract][Full Text] [Related]
34. Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis.
Targownik LE; Bernstein CN; Benchimol EI; Kaplan GG; Singh H; Tennakoon A; Nugent Z; Coward SB; Kuenzig ME; Murthy SK
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2607-2618.e14. PubMed ID: 35247552
[TBL] [Abstract][Full Text] [Related]
35. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
36. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL
Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687
[TBL] [Abstract][Full Text] [Related]
37. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease.
Zisman TL; Cohen RD
Curr Treat Options Gastroenterol; 2007 Jun; 10(3):185-94. PubMed ID: 17547857
[TBL] [Abstract][Full Text] [Related]
39. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.
Lowe SC; Sauk JS; Limketkai BN; Kwaan MR
J Gastrointest Surg; 2021 Jan; 25(1):211-219. PubMed ID: 33140318
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
